Table 2.

Influence of different variables on the anti-S-RBD IgG and neutralizing antibodies (NAb) titers one month (T1) and 5.5 months (T2) after two doses of the BNT162b2 or mRNA-1273 vaccines.

Anti-S-RBD IgG (T1) (BAU/ml)	Beta	Sig.	R2	NAb (T1) (IU/ml)	Beta	Sig.	R2
Gender (female)	0.269	0.015	0.657		0.079	0.194	0.889
Nadir CD4+ T cells/μl	-0.501	0.023			-0.971	0.337
Basal CD4+ T cell count	0.981	<0.001			0.565	<0.001
Vaccine (mRNA-1273)	0.246	0.028			0.232	0.007
% SARS-CoV-2-specific memory-B cells	-0.007	0.968			0.385	<0.001
Anti-S-RBD IgG (T2) (BAU/ml)	Beta	Sig.	R2	NAb (T2) (IU/ml)	Beta	Sig.	R2
Gender (female)	0.116	0.299	0.662		0.129	0.161	0.772
Nadir CD4+ T cells/μl	0.118	0.606			0.047	0.963
Basal CD4+/CD8+ ratio	0.173	0.723			-0.020	0.918
Vaccine (mRNA-1273)	0.429	0.671			0.371	0.004
% SARS-CoV-2-specific memory-B cells	0.516	0.003			0.507	0.001